Objective: To evaluate the effect of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) on motor fluctuations and dyskinesia in advanced Parkinson’s disease (PD) patients during routine care.

Background: LCIG is continuously delivered via percutaneous gastrojejunostomy (PEG-J) in advanced PD patients with motor fluctuations and dyskinesia not adequately reduced by available oral anti-Parkinsonian medications. LCIG treatment significantly improved motor complications and dyskinesia in this registry at interim follow-up (12 months [M]). (ref 1)

Methods: GLORIA is a multinational (18 countries, 75 centres) registry designed to collect efficacy and safety data of routine clinical care use of LCIG over 24M via PEG-J. Daily hours of “off” time and “on” time with dyskinesia were measured by modified Unified Parkinson’s disease Rating Scale Part IV items 39 and 32, respectively. Adverse drug reactions (ADRs) were monitored.

Results: Of the 375 patients enrolled (Table 1), 225 (60%) were LCIG-naïve and 150 (40%) were treated with LCIG for ≥12M before the registry; 258 (69%) completed the 24M follow-up. The mean (SD) levodopa dose was 1412 (606) mg on D1 [n=348] and 1512 (646) mL at M24 [n=257]. The percentage of patients taking concomitant medication (Table 2) ranged 60 – 64% (190/316, 175/273, respectively). LCIG-treated patients had significant decreases from baseline in daily hours of “off” time and “on” time with dyskinesia, which were maintained over 24M.(Figure 1) Forty-six patients (12%) discontinued because of an ADR; device dislocation was the only reason reported by ≥2 patients (0.2%).